2상모집 예정
A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
연구 개요
Researchers are looking for new ways to treat people with B-cell cancers. In this trial, researchers will look at chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). These are blood cancers that affect B-cells in the blood, bone marrow, or lymph nodes. The goals of this trial are to learn about: * The safety of MK-1045 and if participants tolerate it. Tolerate means participants will receive trial treatment unless they need to stop treatment due to health problems. * The number of participants who respond. Respond means the number of cancer cells goes down or signs of cancer go away.
- 스폰서
- 리드: 머크(MSD)
- 적응증
- Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
- 중재
- MK-1045, Acetaminophen (or similar antipyretic), Diphenhydramine (or similar antihistamine), Dexamethasone, Tocilizumab, Tocilizumab biosimilar, Siltuximab
- 목표 등록
- 60명
- 시작일
- 2026-08-21
- 완료(예정)
- 2033-11-16
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.